SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in several oral and poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting taking pl ...

To be completely upfront, small-cap stocks to buy are risky. They’re the equivalent of plus-money bets or plus odds. Let me explain.In the world of sports gambling, you have the option of either wagering on the favorite or the underdog. Favorites are that way for a reason. Still, underdogs can occasionally spark an upset. And these bets can yield exponentially large rewards. You just have to know when to place the bets and for whom.That’s always going to be a tricky endeavor. However, if you’re willing to r ...

A double beat on earnings, plus positive adjustments to certain guidance items, lifted the company's shares.Adaptive Biotechnologies (ADPT 2.25%), a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the cure for the stock market blahs on Wednesday. The commercial-stage biotech reported encouraging quarterly results, and investors signaled approval by trading the stock up by more than 2%. By contrast, the S ...

Investor Relations Presentation Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy ...

Adaptive Biotechnologies Corporation. (NASDAQ:ADPT) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Piskel - CFO Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandberg Tom Stevens - TD Cowen Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2024 Earnings Call. Please note, ...

Adaptive Biotechnologies (ADPT) reported $41.87 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 11.2%. EPS of -$0.33 for the same period compares to -$0.40 a year ago.The reported revenue represents a surprise of -0.78% over the Zacks Consensus Estimate of $42.2 million. With the consensus EPS estimate being -$0.35, the EPS surprise was +5.71%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectatio ...

公司业绩 - 自适应生物技术公司（Adaptive Biotechnologies）每股季度亏损0.33美元 而扎克斯（Zacks）共识估计每股亏损0.35美元 一年前每股亏损0.40美元 该季度报告盈利惊喜为5.71% [1] - 上一季度预期每股亏损0.32美元 实际每股亏损0.30美元 盈利惊喜为6.25% 过去四个季度中 公司有两次超出共识每股收益（EPS）预期 [1] - 2024年3月结束的季度营收为4187万美元 低于扎克斯共识估计0.78% 去年营收为3765万美元 过去四个季度仅一次超出共识营收预期 [1] 股票表现 - 自年初以来 公司股价下跌约34.3% 而标准普尔500指数（S&P 500）上涨8.6% [2] 未来展望 - 股票近期价格走势的可持续性取决于管理层在财报电话会议上的评论 [2] - 公司盈利前景有助于投资者判断股票走向 投资者可自行跟踪盈利预期修正 也可依靠扎克斯排名（Zacks Rank） [3] - 财报发布前 公司的盈利预期修正趋势为混合 在刚刚发布财报后 其扎克斯排名为3（持有） 预计近期股票表现将与市场一致 下一季度共识每股收益估计为 - 0.33美元 营收为4257万美元 当前财年每股收益估计为 - 1.31美元 营收为18510万美元 [4] 行业相关 - 医疗 - 生物医学和遗传学行业在250多个扎克斯行业中目前处于前30% 研究表明 排名前50%的扎克斯行业表现优于排名后50%的行业2倍以上 [5] - 同行业的Prothena公司预计在即将发布的报告中每股季度亏损1.21美元 较去年同期变化 - 36% 过去30天 该季度共识每股收益预期上调0.2% 营收预计为375万美元 较去年同期增长73% 结果预计于5月8日发布 [5][6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-090702 ...

财务业绩 - Adaptive Biotechnologies Corporation于2024年3月31日结束的季度发布了初步财务业绩[3] 公司展望 - 公司未来展望和业绩指引尚未提及[3] 签署报告 - 公司首席执行官Chad Robins于2024年4月5日签署了报告[5]

公司战略 - Adaptive Biotechnologies宣布进行战略审查，并决定内部运营MRD和免疫医学业务[2] - Adaptive Biotechnologies将于2024年4月2日下午1:30在太平洋时间/下午4:30在东部时间举行电话会议，讨论业务更新[9] 财务表现 - 第一季度2024年初步未经审计的收入结果显示总收入约为4100万至4300万美元，较2023年第一季度增长约12%[5] - MRD业务第一季度2024年收入约为3100万至3200万美元，较2023年第一季度增长约47%[6] 高管变动 - Adaptive Biotechnologies宣布首席财务官Tycho Peterson将离开公司，由Kyle Piskel接任[7]